Close this search box.

Cell and gene therapy specialist Minaris expanding

Japanese CDMO Minaris Regenerative Medicine Co. Ltd  will invest US$64.5m to expand its facilities in Europe and Asia.

In Europe, the Showa Denko Materials Co., Ltd. subsidiary will invest US$40.7 million to build a new state-of-the-art facility in proximity to an already existing site in Ottobrunn near Munich, Germany. The new plant will operate according to GMP standards (FDA and EMA) and be dedicated to clinical and commercial manufacturing as well as development services for cell and gene therapies. The multi-storey building with a total of 6,650 sqm will initially more than double Minaris’ existing capacity in Europe by providing additional clean rooms, quality control laboratories, warehousing, cryo-storage and office space. It will have a modular design with the possibilities to go from single room to ball room design and to flexibly change between grade B and grade C configuration. The new facility is expected to be operational by early 2023 and will allow for additional expansion of clean rooms according to client demand and specifications, thus more than tripling the current clean room capacity.

In Asia, the company will establish a new 4,000 sqm facility in Yokohama by 2022, doubling its current capacity for commercial manufacturing of regenerative medicine.